This paper updates endpoint definitions for aortic valve clinical research, providing detailed criteria for evaluating mortality, neurologic events, hospitalization, bleeding, and valve dysfunction. The goal is to improve the homogeneity of data reporting and analysis in future clinical trials involving transcatheter and surgical aortic valve interventions.

Several authors disclose financial ties to medical device companies, which could potentially influence the recommendations made in the document. Specifically, funding from Abbott Vascular, Abiomed, Boston Scientific, Cardinal Health, Cardiovascular System Inc., Edwards LifeSciences, Medtronic, Opsens, Siemens, SoundBite Medical Solutions, Sig.Num, Saranas, Teleflex, and Tryton Medical is disclosed.

This document provides valuable guidance for standardizing clinical research in aortic valve disease. However, it does not present original research or novel findings, and several authors have industry ties. This limits the impact and objectivity of the work, resulting in a rating of 3.